ArticleThe oncologist2025
Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2- breast cancer receiving neoadjuvant chemotherapy.
Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- High TROP-2 expression as a predictor of poor neoadjuvant chemotherapy response in luminal B breast cancer: a retrospective clinicopathological study.BMC cancer · 2026Article
- Trop2 expression, p16 expression status, and histologic subtype in carcinoma of the uterine cervix.Pathology oncology research : POR · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLimited data exists about the associations between TROP2 protein, clinico-pathological characteristics, and outcomes in patients with an early HR+/HER2- breast cancer (BC). PATIENTS AND
methodsTROP2 membranous expression was assessed on tumor biopsy by immunohistochemistry (IHC) in 70 consecutive patients with HR+/HER2- BC who are eligible for neoadjuvant chemotherapy (NAC). TROP2 expression was correlated to initial clinico-pathological parameters and pathological response post-NAC. Furthermore, Transcriptomics analysis of TACSTD2 using SCAN-B and GSE81538 datasets was performed and correlated with clinico-pathological parameters and survival.
resultsAll patients showed TROP2 IHC expression, with intermediate and high expression in 68.57% and 31.43%, respectively. High TROP2 expression showed a significant correlation with high Ki-67 pre-NAC (P = .017), while no significant correlation with pCR or residual cancer burden. High TACSTD2 expression was associated with significantly lower histological grade (P < .0001), earlier tumor stage (P < .0001), smaller tumor size (< 20 mm, P < .0001), lower Ki-67 (P < .0001), and longer overall-survival (HR = 0.76; P = .0008), recurrence-free survival (RFS; HR = 0.64; P = .0001) and distant-RFS (HR = 0.64; P = .0011).
conclusionsIn this study, TROP2 expression by IHC was observed in all HR+/HER2- BC cases, and was not significantly correlated with pCR to NAC. In contrast, TACSTD2 expression, which was significantly positively correlated with survival in the same population, suggests a favorable prognostic value at the transcript level. This finding warrants further investigation in future studies, particularly focusing on TACSTD2 expression at the mRNA rather than the protein level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.